0001193125-22-015468.txt : 20220124 0001193125-22-015468.hdr.sgml : 20220124 20220124073101 ACCESSION NUMBER: 0001193125-22-015468 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20220124 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220124 DATE AS OF CHANGE: 20220124 FILER: COMPANY DATA: COMPANY CONFORMED NAME: TScan Therapeutics, Inc. CENTRAL INDEX KEY: 0001783328 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 825282075 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-40603 FILM NUMBER: 22547550 BUSINESS ADDRESS: STREET 1: 830 WINTER STREET CITY: WALTHAM STATE: MA ZIP: 02451 BUSINESS PHONE: 857-399-9500 MAIL ADDRESS: STREET 1: 830 WINTER STREET CITY: WALTHAM STATE: MA ZIP: 02451 8-K 1 d298787d8k.htm 8-K 8-K
false 0001783328 0001783328 2022-01-24 2022-01-24

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 24, 2022

 

 

TSCAN THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-40603   82-5282075

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(I.R.S. Employer

Identification No.)

830 Winter Street

Waltham, Massachusetts 02451

(Address of principal executive offices, including zip code)

(857) 399-9500

(Registrant’s telephone number, including area code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trade

Symbol(s)

  

Name of each exchange

on which registered

Common Stock, $0.0001 par value per share   TCRX   The Nasdaq Global Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company  ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

 

 

 

Item 8.01

Other Events

On January 24, 2022, TScan Therapeutics, Inc. (the “Company”) issued a press release announcing that the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application to evaluate TSC-100 for the treatment of patients with hematologic malignancies who are undergoing allogeneic hematopoietic cell transplantation. The press release also announced that the FDA separately indicated that the Company’s IND for TSC-101 targeted to the lineage-specific blood cell antigen HA-2 has been placed on hold pending additional assessment of the risk of off-tumor reactivity for TSC-101. The full text of the press release issued in connection with the announcement is filed as Exhibit 99.1 on this Current Report on Form 8-K.

 

Item 9.01.

Exhibits

(d) Exhibits

 

Exhibit
No.		    Description
99.1    Press release issued by TScan Therapeutics, Inc. on January 24, 2022
104    Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    TScan Therapeutics, Inc.
Date: January 24, 2022     By:  

/s/ Brian Silver

      Brian Silver
      Chief Financial Officer
 EX-99.1 2 d298787dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

 

LOGO

TScan Therapeutics Announces FDA Clearance of Investigational New Drug

Application for TSC-100 for the Treatment of Hematologic Malignancies

- Phase 1 trial of TSC-100 expected to initiate in the first half of 2022 –

- IND for TSC-101 on hold pending additional assessment of the risk of off-tumor reactivity –

WALTHAM, Mass., Jan. 24, 2022 — TScan Therapeutics, Inc. (Nasdaq: TCRX), a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced that the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application to evaluate TSC-100 for the treatment of patients with hematologic malignancies who are undergoing allogeneic hematopoietic cell transplantation (HCT). The target of TSC-100 is the minor histocompatibility antigen HA-1, which is a lineage-specific antigen found on blood cells. The Company will now submit the clinical protocol to Institutional Review Boards (IRB) for the initial study sites and expects to begin dosing patients in the first half of 2022.

TSC-101 is targeted to the lineage-specific blood cell antigen HA-2, which is a novel target for cell therapy. The Company received a brief communication from the FDA indicating that the TSC-101 IND has been placed on hold pending additional assessment of the risk of off-tumor reactivity for TSC-101. The Company expects to receive further written communication from the FDA in the near future and plans to work with the agency to resolve its questions as quickly as possible.

“FDA clearance of our IND application for TSC-100 is an important milestone for our lead liquid tumor program as it marks the first clinical-stage product candidate to advance from our pipeline of therapies geared to treat unmet needs in major cancer indications,” said David Southwell, President and Chief Executive Officer. “We are excited about the potential of both TSC-100 and TSC-101 to prevent relapse in leukemia patients following HCT. We are looking forward to initiating our Phase 1 multi-arm clinical trial in the first half of this year, with preliminary data expected in the second half of 2022. We will be opening the TSC-101 arm upon FDA clearance of the TSC-101 IND.”

“FDA clearance of our TSC-100 IND is significant as it allows us to move forward with the umbrella clinical protocol for our hematologic cancer study,” said Gavin MacBeath, Chief Scientific Officer. “This is a great accomplishment for our organization and validation of our TCR discovery platform. Importantly, the INDs for TSC-100 and TSC-101 were based on our proprietary T-Integrate cell engineering platform, which includes our advanced non-viral vector and our in-house GMP manufacturing capabilities. We intend to use this same platform to develop enhanced TCR-T cell therapies for our solid tumor program.”

With the acceptance of the IND for TSC-100 in hematologic malignancies, TScan plans to initiate a multi-arm Phase 1 umbrella trial designed to evaluate TSC-100 compared to standard-of-care in patients who are undergoing allogeneic HCT. Pending acceptance from the FDA regarding the IND for TSC-101, the Company will then initiate the TSC-101 arm of this trial in the same patient population. Primary endpoints include safety and dose-finding, and secondary and exploratory endpoints include relapse rate versus standard-of-care as well as qualitative biological readouts including minimal residual disease and kinetics of donor chimerism. Once the recommended Phase 2 dose has been identified, the study will transition to Phase 2 to assess relapse rates of treated patients versus the standard-of-care arm.

About TScan Therapeutics, Inc.

TScan is a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The Company’s lead liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. The Company is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors. The Company has developed and continues to build its ImmunoBank, the most extensive collection of known and novel solid tumor targets across different HLA types in the TCR field.

Forward-Looking Statements

This press release may contain forward-looking statements and information within the meaning of The Private Securities Litigation Reform Act of 1995 and other federal securities laws. The use of words such as “may,” “will,” “could,” “should,” “expects,” “intends,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “projects,” “seeks,” “endeavor,” “potential,” “continue” or the negative of such words or other similar expressions can be used to identify forward-looking statements. The express or implied forward-looking statements included in this press release are only predictions and are subject to a number of risks, uncertainties and assumptions, including, without limitation risks set forth under the caption “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of TScan’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2021, which is on file with the Securities and Exchange Commission (SEC) and available on the SEC’s website at https://www.sec.gov/. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this press release may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. You should not rely upon forward-looking statements as predictions of future events. Although TScan believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected in the forward-looking statements will be achieved or occur. Moreover, except as required by law, neither TScan nor any other person assumes responsibility for the accuracy and completeness of the forward-looking statements included in this press release. Any forward-looking statement included in this press release speaks only as of the date on which it was made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.

Contact

TScan Therapeutics, Inc.

Heather Savelle

VP, Investor Relations

857-399-9840

hsavelle@tscan.com

EX-101.SCH 3 tcrx-20220124.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 4 tcrx-20220124_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company Entity Ex Transition Period Entity Ex Transition Period EX-101.PRE 5 tcrx-20220124_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 g298787g0124024451004.jpg GRAPHIC begin 644 g298787g0124024451004.jpg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end XML 7 R1.htm IDEA: XBRL DOCUMENT v3.21.4
Document and Entity Information
Jan. 24, 2022
Cover [Abstract]  
Amendment Flag false
Entity Central Index Key 0001783328
Document Type 8-K
Document Period End Date Jan. 24, 2022
Entity Registrant Name TSCAN THERAPEUTICS, INC.
Entity Incorporation State Country Code DE
Entity File Number 001-40603
Entity Tax Identification Number 82-5282075
Entity Address, Address Line One 830 Winter Street
Entity Address, City or Town Waltham
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02451
City Area Code (857)
Local Phone Number 399-9500
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, $0.0001 par value per share
Trading Symbol TCRX
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Entity Ex Transition Period false
XML 8 d298787d8k_htm.xml IDEA: XBRL DOCUMENT 0001783328 2022-01-24 2022-01-24 false 0001783328 8-K 2022-01-24 TSCAN THERAPEUTICS, INC. DE 001-40603 82-5282075 830 Winter Street Waltham MA 02451 (857) 399-9500 false false false false Common Stock, $0.0001 par value per share TCRX NASDAQ true false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( . [.%0'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " #@.SA4^OFZ_^\ K @ $0 &1O8U!R;W!S+V-O&ULS9)1 M2\,P$,>_BN2]O315P=#E9<,G!<&!XEM(;EM8TX;DI-VWMXU;A^@'\#%W__SN M=W"-"=+T$5]B'S"2PW0S^K9+TH05.Q %"9#, ;U.Y93HIN:NCU[3](Q["-H< M]1Y!<'X/'DE;31IF8!$6(E.--=)$U-3',]Z:!1\^8YMAU@"VZ+&C!%59 5/S MQ' :VP:N@!E&&'WZ+J!=B+GZ)S9W@)V38W)+:AB&\;N&Z M1+HS./U*3M(IX(I=)K_5Z\WVD2G!A2AX58C;;25DS>7=P\?L^L/O*NQ[ZW;N M'QM?!%4#O^Y"?0%02P,$% @ X#LX5)E&UL[5I;<]HX%'[OK]!X9_9M"\8V@;:T$W-I=MNTF83M M3A^%$5B-;'EDD81_OTV23;J;/ 0LZ?O.14?GZ#AY\^XN8NB&B)3R M> +]O6N[!3+ MUES@6QHO(];JM-O=5H1I;*$81V1@?5XL:$#05%%:;U\@M.4?,_@5RU2-9:,! M$U=!)KF(M/+Y;,7\VMX^9<_I.ATR@6XP&U@@?\YOI^1.6HCA5,+$P&IG/U9K MQ]'22(""R7V4!;I)]J/3%0@R#3LZG5C.=GSVQ.V?C,K:=#1M&N#C\7@XMLO2 MBW A(5M>5 TR M6'!VULS2 Y9>*?IUE!K9';O=05SP6.XYB1'^QL4$UFG2&98T1G*=D 4. #?$ MT4Q0?*]!MHK@PI+27)#6SRFU4!H(FLB!]4>"(<7K;YH] M5Z%82=J$^!!&&N*<<^9ST6S[!Z5&T?95O-RCEU@5 9<8WS2J-2S%UGB5P/&M MG#P=$Q+-E L&08:7)"82J3E^34@3_BNEVOZKR2.FJW"$2M"/F(9 M-AIRM1:!MG&IA&!:$L;1>$[2M!'\6:PUDSY@R.S-D77.UI$.$9)>-T(^8LZ+ MD!&_'H8X2IKMHG%8!/V>7L-)P>B"RV;]N'Z&U3-L+([W1]072N0/)J<_Z3(T M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+ M.7\N?<^E[[GT/:'2MSAD6R4)RU3393>* M$IY"&V[I4_5*E=?EK[DHN#Q;Y.FOH70^+,_Y/%_GM,T+,T.WF)&Y M"M-2D&_#^>G%>!KB.=D$N7V85VWGV-'1^^?!4;"C[SR6'<>(\J(A[J&&F,_# M0X=Y>U^89Y7&4#04;6RL)"Q&MV"XU_$L%.!D8"V@!X.O40+R4E5@,5O& RN0 MHGQ,C$7H<.>77%_CT9+CVZ9EM6ZO*7<9;2)2.<)IF!-GJ\K>9;'!51W/55OR ML+YJ/;053L_^6:W(GPP13A8+$DACE!>F2J+S&5.^YRM)Q%4XOT4SMA*7&+SC MYL=Q3E.X$G:V#P(RN;LYJ7IE,6>F\M\M# DL6XA9$N)-7>W5YYNTB42%(JP# 4A M%W+C[^^3:G>,U_HL@6V$5#)DU1?*0XG!/3-R0]A4)?.NVB8+A=OB5,V[&KXF M8$O#>FZ=+2?_VU[4/;07/4;SHYG@'K.' MYA,L0Z1^P7V*BH 1JV*^NJ]/^26<.[1[\8$@F_S6VZ3VW> ,?-2K6J5D*Q$_ M2P=\'Y(&8XQ;]#1?CQ1BK::QK<;:,0QY@%CS#*%F.-^'19H:,]6+K#F-"F]! MU4#E/]O4#6CV#30,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04 M" #@.SA40K/1/50$ #<$ & 'AL+W=O13&];H3')1\=)_9#'+&VK MA$MXLE$Z9@::>NNDB>8LR(/BR*&N>^/$3,C6>)3?6^CQ2&4F$I(O-$FS.&;Z M_8Y':G?;\EK'&\]B&QI[PQF/$K;E2VZ^)0L-+:=4"43,92J4))IO;EL3[^,= M[=F _(U?!=^E)]?$=F6MU*MMS(/;EFN)>,1]8R48_+SQ*8\BJP0#I]5'](>\\=&;-4CY5T8L(3'C;&K1(P#5?S:( 3TH[*TFAX*B#.C.^5GT&2#6$R(#-IA'DGNR1^3=6HT#.&?B&2G ME.SDDMTSDA/H<)!W^B%BV[HNXO$;%J4B6'%U4YY#N*9!H%D': [XGG_E[ M'1&NY+JNUQ]T.G2 8/5*K!XJ5I;$ZCWA=2QX^.#Z,P)Q4T+<7 :QX%HH6YH! M@0*OY<&5C@7YW8;*8 M?5O-I\LK,G^:MA'$08DXN 1Q+GVE$Z7SN4R6!A)(IBJ#>H.R4T$M,RY\/T/H MAB7=\!*Z!Q%Q\I3%:Z[K0' -J/CKKGOC=A >SZU=KD!S0ZQX=4+??PPA/?-J[A' 2!)JGZ=7Q@GR!]\A763N4#9*#CDM>A#3@ MKW ;5A ,M/)KC_XOT*EM*4U6:E>_G.!R+RPR(8LQM,KW/=RX_XU63 A@6VCU M)J1?GT1<\W&"H55+@7?16E"B+51J8$WX721G)VJ#HDN[/0]CJ]8##W?T? 0G ML.<[CX(+_##H]7_$4*I5P[^$>O521\(41
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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.4 html 1 118 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.tscan.com//20220124/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d298787d8k.htm d298787dex991.htm tcrx-20220124.xsd tcrx-20220124_lab.xml tcrx-20220124_pre.xml http://xbrl.sec.gov/dei/2021 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d298787d8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "d298787d8k.htm" ] }, "labelLink": { "local": [ "tcrx-20220124_lab.xml" ] }, "presentationLink": { "local": [ "tcrx-20220124_pre.xml" ] }, "schema": { "local": [ "tcrx-20220124.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "https://xbrl.sec.gov/naics/2021/naics-2021.xsd" ] } }, "elementCount": 24, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 118, "memberCustom": 0, "memberStandard": 0, "nsprefix": "tcrx", "nsuri": "http://www.tscan.com/20220124", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d298787d8k.htm", "contextRef": "duration_2022-01-24_to_2022-01-24", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.tscan.com//20220124/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d298787d8k.htm", "contextRef": "duration_2022-01-24_to_2022-01-24", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.tscan.com//20220124/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.tscan.com//20220124/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.tscan.com//20220124/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.tscan.com//20220124/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.tscan.com//20220124/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.tscan.com//20220124/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.tscan.com//20220124/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.tscan.com//20220124/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.tscan.com//20220124/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.tscan.com//20220124/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.tscan.com//20220124/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.tscan.com//20220124/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.tscan.com//20220124/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.tscan.com//20220124/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.tscan.com//20220124/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.tscan.com//20220124/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.tscan.com//20220124/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.tscan.com//20220124/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.tscan.com//20220124/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.tscan.com//20220124/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.tscan.com//20220124/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.tscan.com//20220124/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.tscan.com//20220124/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r7": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" } }, "version": "2.1" } ZIP 15 0001193125-22-015468-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-22-015468-xbrl.zip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